In phase Ib clinical trial, omalizumab therapy showed some efficacy on disease activity in SLE patients with elevated level of serum autoreactive IgE antibody (148), which indicates the role of autoreactive IgE in the pathogenesis of SLE. Here, IGHE is linked to systemic lupus erythematosus.